Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

ABSTRACT: First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

PROVIDER: PRJNA819052 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR18454600_1.fastq.gz	Fastqsanger.gz
	SRR18454600_2.fastq.gz	Fastqsanger.gz
	SRR18454700_1.fastq.gz	Fastqsanger.gz
	SRR18454700_2.fastq.gz	Fastqsanger.gz
	SRR18454601_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 340

Similar Datasets

First-in-class microbial ecosystem therapeutics 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumours (MET4-IO Trial)

Project description:The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICI) in humans, and causally implicated in ICI responsiveness in animal models. Therapeutic augmentation of the microbiome in ICI recipients is being investigated in multiple ongoing human clinical trials. We conducted an early phase clinical trial of a cultivated, orally-delivered 30-species microbial consortium (microbial ecosystem therapeutic-4, MET4) designed for co-administration with ICIs and assessed safety, tolerability and ecological responses in patients with advanced solid tumors.

2022-03-26 | GSE199245 | GEO

Paired tumour biopsy gene expression data from patients with solid tumours, before and after combination treatment.

Project description:Gene expression quantification of PanCancer IO genes from paired tumour biopsies from 24 patients with pan-cancer solid tumours, before and after treatment with MTL-CEBPA and pembrolizumab.

2024-10-23 | GSE233860 | GEO

RNAseq analysis of tumours from GEMMS animals to determine the effect of different aPDL1 combinations on lung tumours in situ

Project description:This study aims to identify combination treatments capable of inducing improved IO responses in lung tumours and thus, help guide decisions on the next combination arms for the HUDSON trial (post-IO). For that purpose, a lung tumour GEMM model was treated with either vehicle, PD-L1, ATR, ATR/PD-L1; Cisplatin/PD-L1/Ctla4 or VEGFR/PD-L1 and tumours collected for transcriptional profiling.

2024-01-29 | E-MTAB-13704 | biostudies-arrayexpress

Nymphalis io

Project description:Inachis io overview

| PRJNA693935 | ENA

Ia io

Project description:Ia io overview

| PRJNA888189 | ENA

CD137-CIS IO

Project description:CD137-CIS IO

| PRJNA663842 | ENA

Ia io

Project description:Ia io Raw sequence reads

| PRJNA1081129 | ENA

Ia io

Project description:Ia io Genome sequencing and assembly

| PRJNA748544 | ENA

Ia io

Project description:Genome sequencing and assembly of Ia io

| PRJNA782023 | ENA

Specific endothelical cells govern nanoparticle entry into solid tumours

Project description:We sequenced the transcroptome of isolated nanoparticle positive and nanoparticle negative tumour endothelial cells from mouse 4T1 mammary tumours

2021-09-07 | GSE172496 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data